Drug intelligence / Profile preview

SPVN70

Development stage: Preclinical
Lead developer: SparingVision
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
Administration: Ophthalmic

Overview

SPVN70 is a genomic medicine under development for the treatment of ocular conditions, specifically targeting eye diseases with high unmet need. It leverages Intellia Therapeutics' in-vivo CRISPR/Cas9 genome editing technology, with SparingVision leading and funding all preclinical and clinical development. The collaboration also focuses on co-developing novel adeno-associated virus (AAV) and lipid nanoparticle (LNP) delivery methods optimized for retinal administration. This gene-editing approach aims to address mutations that are not amenable to traditional gene replacement therapies.

Targets

DNA

Beyond the preview

Go deeper on SPVN70.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPVN70.

Explore the full profile